The epidemiologic burden of hepatitis C virus infection in Latin America

Szabo, Shelagh M.; Bibby, M.; Yuan, Yong; Donato, B.M.K.; Jiménez-Méndez, Ricardo; Castañeda‐Hernández, Gilberto; Rodrı́guez-Torres, Maribel; Levy, Adrian R.

doi:10.1016/s1665-2681(19)31435-8

Cited by 35 publications

(20 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our estimates for HCV prevalence in Colombia and Costa Rica are consistent with those previously reported (1-2.5%) but somehow lower than what has been published in Argentina (0.34 vs 2-2.5 in literature) (11). Data for Spain was also consistent with that reported in western European countries (1.6%) (12).…”

Section: Discussionsupporting

confidence: 91%

Hepatitis C virus seroprevalence in the general female population from 8 countries

Quesada

Whitby

Benavente

et al. 2015

Journal of Clinical Virology

View full text Add to dashboard Cite

Background Hepatitis C virus (HCV) infection is a significant global health issue because it is widespread and persistent and can cause serious liver diseases. Objectives The aim of this study is to estimate HCV prevalence in women from the general population in different geographical areas worldwide and to assess the potential role of sexual behaviour in the virus transmission. Study design Each participating centre recruited a random sample of women from the general population aged from less than 20 to more than 75 years. The study included 8,130 women from 8 countries with information on sociodemographic factors, reproductive and sexual behaviour, smoking habit and HPV DNA through individual interviews. A blood sample was also collected to perform serological tests. We estimated the prevalence ratios associated to HCV to evaluate the effect of sexual behaviour in viral transmission. Results Women were reactive to a minimum of two HCV antigens, including at least one non structural protein were considered as positive (33% of the samples were classified as positive, 40% as negative, and 27% as indeterminate (N=402), that were considered as not positive). The age-adjusted HCV seroprevalence varied significantly by regions (0.3 % in Argentina to 21.1% in Nigeria). We found no association between HCV prevalence and age, educational level, smoking habit and any of the available variables for sexual behaviour and reproductive history. Conclusions This large study showed heterogeneous distribution of HCV seroprevalence in female and provides evidence of the null impact of sexual behaviour in HCV transmission.

show abstract

Section: Discussionsupporting

confidence: 91%

Hepatitis C virus seroprevalence in the general female population from 8 countries

Quesada

Whitby

Benavente

et al. 2015

Journal of Clinical Virology

View full text Add to dashboard Cite

show abstract

“…In future decades, it is expected that, particularly in the developing countries, the burden of HCV disease increases due to the absence of an effective vaccine, the insufficient amount of public awareness, and preventive measures 13,14,17. Therefore, regardless of the great therapeutic advances, improvements in HCV surveillance, epidemiologic mapping, testing, prevention, and therapy are urgently needed.…”

Section: Resultsmentioning

confidence: 99%

“…In recent years, different studies have addressed the epidemiology of chronic HCV infection in Latin America 14,15. Nonetheless, there is still a paucity of information in the region, since most of the available data come from spontaneous demand studies in specific groups, which do not faithfully represent the prevalence in the general population 16,17…”

Section: Hcv In Latin America: Burden Of Infection and Accessibility mentioning

confidence: 99%

“…Despite this limitation, it is estimated an average prevalence rate for HCV of 2.0%±0.25% in the adult population, which represents at least 10 million individuals who are anti-HCV positive in Latin America 14,17,18. On the whole, Latin America has the lowest HCV prevalence compared with others regions around the world.…”

Section: Hcv In Latin America: Burden Of Infection and Accessibility mentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Trinks

Caputo

Hulaniuk³

et al. 2017

PGPM

View full text Add to dashboard Cite

In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excellent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 1 infection and the significant association of Native American ancestry with risk predictive single-nucleotide polymorphisms (SNPs) in IFNL4 and ITPA genes highlight the need to implement new treatment regimens in these populations. However, the universal accessibility to DAAs is still not a reality in the region as their high cost is one of the major, although not the only, limiting factors for their broad implementation. Therefore, under these circumstances, could the assessment of host genetic markers be a useful tool to prioritize DAA treatment until global access to these new drugs can be achieved? This review will summarize the scientific evidences and the potential implications of HCV pharmacogenomics in this rapidly evolving era of anti-HCV drug development.

show abstract

“…Latin American, with about eight million HCV-infected persons, has a relative low HCV prevalence (1.3%) in comparison with others geographic regions around the world; although the precise prevalence of this virus greatly vary between countries and between country regions (Szabo et al, 2012;Méndez-Sánchez et al, 2010). Genotypes 1 and 3 were the most prevalent HCV genotypes in Latin America (Kershenobich et al, 2011) HCV epidemics in Argentina and Brazil are characterized by multiple introductions events of subtypes 1a, 1b and 3a, followed by subsequent local dispersion of some of those viral strains (Culasso et al, 2012;del Pino et al, 2013;Lampe et al, 2013;Ré et al, 2011).…”

Section: Introductionmentioning

confidence: 99%